Picture of Egetis Therapeutics AB (publ) logo

EGTX Egetis Therapeutics AB (publ) Share Price

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-8.07%
3m-4.74%
6m-14%
1yr-30.04%
Volume Change (%)
10d/3m-36.35%
Price vs... (%)
52w High-54.58%
50d MA-11.55%
200d MA-27.28%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-18.29%
Return on Equity-18.63%
Operating Margin-550.52%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Egetis Therapeutics AB (publ) EPS forecast chart

Profile Summary

Egetis Therapeutics AB (publ), formerly PledPharma AB (publ) is a Sweden-based pharmaceutical drug development company, focusing on projects in late-stage development for treatment of diseases with unmet medical needs in the orphan drug segment. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.

Directors

Last Annual
December 31st, 2021
Last Interim
June 30th, 2022
Incorporated
January 1st, 1970
Public Since
April 7th, 2011
No. of Shareholders
6,895
No. of Employees
13
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
se flag iconOMX Nordic Exchange Stockholm
Shares in Issue
214,589,128

EGTX Share Price Performance

Upcoming Events for EGTX

Q3 2022 Egetis Therapeutics AB (publ) Earnings Release

Q4 2022 Egetis Therapeutics AB (publ) Earnings Release

Similar to EGTX

Picture of 2cureX AB logo

2cureX AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Abliva AB logo

Abliva AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Acousort AB logo

Acousort AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Acousort AB logo

Acousort AB

se flag iconOMX Nordic Exchange Stockholm

Picture of Active Biotech AB publ logo

Active Biotech AB publ

se flag iconOMX Nordic Exchange Stockholm

FAQ

Or unlock with your email

Or unlock with your email